AAPL   321.75 (-0.03%)
MSFT   183.03 (+0.11%)
FB   228.04 (-1.67%)
AMZN   2,468.95 (-0.08%)
NVDA   350.76 (-0.42%)
CGC   16.51 (+0.12%)
GE   6.94 (+2.66%)
TSLA   902.35 (+0.47%)
AMD   52.93 (-1.31%)
T   31.01 (+0.23%)
F   5.96 (+1.53%)
BA   154.27 (+1.90%)
AAPL   321.75 (-0.03%)
MSFT   183.03 (+0.11%)
FB   228.04 (-1.67%)
AMZN   2,468.95 (-0.08%)
NVDA   350.76 (-0.42%)
CGC   16.51 (+0.12%)
GE   6.94 (+2.66%)
TSLA   902.35 (+0.47%)
AMD   52.93 (-1.31%)
T   31.01 (+0.23%)
F   5.96 (+1.53%)
BA   154.27 (+1.90%)
AAPL   321.75 (-0.03%)
MSFT   183.03 (+0.11%)
FB   228.04 (-1.67%)
AMZN   2,468.95 (-0.08%)
NVDA   350.76 (-0.42%)
CGC   16.51 (+0.12%)
GE   6.94 (+2.66%)
TSLA   902.35 (+0.47%)
AMD   52.93 (-1.31%)
T   31.01 (+0.23%)
F   5.96 (+1.53%)
BA   154.27 (+1.90%)
AAPL   321.75 (-0.03%)
MSFT   183.03 (+0.11%)
FB   228.04 (-1.67%)
AMZN   2,468.95 (-0.08%)
NVDA   350.76 (-0.42%)
CGC   16.51 (+0.12%)
GE   6.94 (+2.66%)
TSLA   902.35 (+0.47%)
AMD   52.93 (-1.31%)
T   31.01 (+0.23%)
F   5.96 (+1.53%)
BA   154.27 (+1.90%)
Log in

NASDAQ:ACADACADIA Pharmaceuticals Stock Price, Forecast & News

$48.51
-0.38 (-0.78 %)
(As of 06/2/2020 09:48 AM ET)
Add
Compare
Today's Range
$48.51
Now: $48.51
$48.99
50-Day Range
$42.85
MA: $49.15
$52.55
52-Week Range
$21.56
Now: $48.51
$53.70
Volume733 shs
Average Volume1.08 million shs
Market Capitalization$7.56 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.8
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Read More
ACADIA Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.25 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACAD
CUSIPN/A
Phone858-558-2871

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$339.08 million
Book Value$4.54 per share

Profitability

Net Income$-235,260,000.00

Miscellaneous

Employees465
Market Cap$7.56 billion
Next Earnings Date7/29/2020 (Estimated)
OptionableOptionable

Receive ACAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.

ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

How has ACADIA Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

ACADIA Pharmaceuticals' stock was trading at $36.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ACAD stock has increased by 31.6% and is now trading at $48.51. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ACADIA Pharmaceuticals?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 2 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ACADIA Pharmaceuticals.

When is ACADIA Pharmaceuticals' next earnings date?

ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for ACADIA Pharmaceuticals.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) posted its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.09. The biopharmaceutical company had revenue of $90.07 million for the quarter, compared to the consensus estimate of $90.76 million. ACADIA Pharmaceuticals had a negative return on equity of 39.40% and a negative net margin of 64.99%. The firm's quarterly revenue was up 43.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.59) earnings per share. View ACADIA Pharmaceuticals' earnings history.

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals updated its FY 2020 After-Hours earnings guidance on Thursday, May, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $420-450 million, compared to the consensus revenue estimate of $449.8 million.

What price target have analysts set for ACAD?

16 brokers have issued 1-year price targets for ACADIA Pharmaceuticals' stock. Their forecasts range from $31.00 to $72.00. On average, they expect ACADIA Pharmaceuticals' share price to reach $56.50 in the next year. This suggests a possible upside of 16.5% from the stock's current price. View analysts' price targets for ACADIA Pharmaceuticals.

Has ACADIA Pharmaceuticals been receiving favorable news coverage?

News headlines about ACAD stock have been trending very positive recently, according to InfoTrie. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ACADIA Pharmaceuticals earned a media sentiment score of 3.5 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutACADIA Pharmaceuticals.

Who are some of ACADIA Pharmaceuticals' key competitors?

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), Sarepta Therapeutics (SRPT), Celgene (CELG), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Synergy Pharmaceuticals (SGYP), Netflix (NFLX), Omeros (OMER) and Citigroup (C).

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the following people:
  • Mr. Stephen R. Davis, CEO & Director (Age 58)
  • Dr. Srdjan R. Stankovic, Pres (Age 62)
  • Mr. Michael J. Yang, Exec. VP & Chief Commercial Officer (Age 57)
  • Ms. Elena H. Ridloff C.F.A., CFA, Exec. VP & CFO (Age 39)
  • Mr. Eric Alejandro Miller, Controller & Principal Accounting Officer (Age 40)

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.53%), State Street Corp (2.59%), Nuveen Asset Management LLC (1.29%), Geode Capital Management LLC (1.11%), Janus Henderson Group PLC (0.96%) and First Trust Advisors LP (0.92%). Company insiders that own ACADIA Pharmaceuticals stock include Austin D Kim, Bros Advisors Lp Baker, Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic and Stephen Davis. View institutional ownership trends for ACADIA Pharmaceuticals.

Which institutional investors are selling ACADIA Pharmaceuticals stock?

ACAD stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Morgan Stanley, Morgan Stanley, Sphera Funds Management LTD., Nuveen Asset Management LLC, UBS Group AG, Squarepoint Ops LLC, and BlackRock Inc.. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Austin D Kim, Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic, and Stephen Davis. View insider buying and selling activity for ACADIA Pharmaceuticals.

Which institutional investors are buying ACADIA Pharmaceuticals stock?

ACAD stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Frontier Capital Management Co. LLC, Rock Springs Capital Management LP, Pictet Asset Management Ltd., Rice Hall James & Associates LLC, Rice Hall James & Associates LLC, Wellington Management Group LLP, and MERIAN GLOBAL INVESTORS UK Ltd. View insider buying and selling activity for ACADIA Pharmaceuticals.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $48.51.

How big of a company is ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals has a market capitalization of $7.56 billion and generates $339.08 million in revenue each year. The biopharmaceutical company earns $-235,260,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. ACADIA Pharmaceuticals employs 465 workers across the globe.

What is ACADIA Pharmaceuticals' official website?

The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.